泰嘉在ACSPCI术中的应用演示幻灯片.pptVIP

A pooled analysis of the Oasis Registry, Oasis-2 and CURE showed a five-fold increase in the risk of death at 30 days in patients who had a bleeding event, compared to those who did not. In GRACE, a four- to five-fold increase in the risk of death at 30 days was shown in patients who had a bleeding event, compared to those who did not, whatever the initial clinical subset. The dosage of drugs has a major impact on the risk of bleeding. In the CRUSADE registry, it was shown that a sizeable proportion of the population had inappropriate dosage – major excess in dosage, whatever the therapeutic agent considered. Excess dosage led to major increases in the risk of bleeding, particularly with the use of inhibitors. It was also shown in this registry that elderly patients, and those with renal failure, frequently had errors in the dosage of these drugs. 试验目的: 确定适合中国患者长期使用的剂量 50mg泰嘉与250mg噻氯匹定疗效对比研究 泰嘉在中国临床50mg试验 50mg泰嘉与250mg噻氯匹定疗效对比研究——上海中山、瑞金、华山、长海、天津医科大学附二医院等多中心双盲随机试验 泰嘉50mg血小板聚集抑制率 服药前 ８天 ４周末 ＡＤＰ０．５ ＡＤＰ１．０ 50mg 氯吡格雷使中国人的血小板聚集率抑制达46-53% 泰嘉血小板聚集率（%） 泰嘉50mg和噻氯匹定250mg比较 噻氯匹定 泰嘉 服药前 ８天 ４周末 血小板聚集率(%) 50mg氯吡格雷应用试验（中保办基金试验）解放军总医院南楼老年心内科 司全金 李小鹰 91例老年冠心病患者 阿司匹林组 (100mg/dx8w) 泰嘉组 (50mg/dx8w) 复方丹参滴丸组 (10粒 3次/dx8w) 随机分为三组 观察指标 试验前后血小板聚集率变化 胃粘膜出血（全部用胃镜检查） 中性粒细胞及血小板影响 凝血三项改变 中华老年心脑血管病杂志2006，Vol 8, No 4 试验结果 各组试验前后血小板聚集(PAG) 组别 例数 治疗前 治疗后 治疗前后差值 A.阿司匹林组 31 0.49±0.09 0.36±0.1★ -0.14±0.12☆ B.泰嘉组 30 0.53±0.15 0.3±0.08★ -0.23±0.16☆* C.丹参滴丸组 30 0.47±0.14 0.48±0.15 0.005±0.08 泰嘉组使血小板聚集率降低43.4% 阿司匹林组降低28.5% 丹参滴丸组几无变化 注：泰嘉组与A组、C组比较，☆P＜0.05；与治疗前比较，★P＜0.05； 各组胃粘膜出血情况（全部胃镜检查） 阿司匹林组3例（9.7%) 氯吡格雷组1例 (3.3%) 丹参滴丸组1例 (3.3%) 泰嘉更安全 PCI术后氯吡格雷两种剂量的治疗效果分析第一军医大学珠江医院心内科 试验目的 评价50mg和75mg氯吡格雷在PCI后的治疗效果 试验方法 105例PCI患者分为两组,各服用氯吡 格雷50mg和75 mg,随防3个月以上 试验方法 R 105例PTCA支架术患者 泰嘉50mg 3 months 氯吡格雷75mg 3 mont